Table 1 Characteristics of Participants Cohorts Before and After Matching

Age, y

0.273

0.034

Mean (SD)

64.4 (12.7)

68.0 (13.4)

68.4 (11.8)

68.0 (13.4)

Center

0.316

< 0.001

Yale

286 (19.5%)

22 (32.4%)

88 (32.4%)

22 (32.4%)

Vanderbilt

484 (32.9%)

18 (26.5%)

72 (26.5%)

18 (26.5%)

Kaiser Permanente

298 (20.3%)

14 (20.6%)

56 (20.6%)

14 (20.6%)

UW

402 (27.3%)

14 (20.6%)

56 (20.6%)

14 (20.6%)

Gender

0.109

0.008

Female

552 (37.6%)

22 (32.4%)

94 (34.6%)

22 (32.4%)

Race

0.346

< 0.001

White

1201 (81.7%)

59 (86.8%)

236 (86.8%)

59 (86.8%)

Black/African American

186 (12.7%)

9 (13.2%)

36 (13.2%)

9 (13.2%)

Other

83 (5.7%)

0 (0%)

0

0

Baseline AKI status

0.062

< 0.001

Yes

737 (50.1%)

32 (47.1%)

128 (47.1%)

32 (47.1%)

ICU

0.065

0.016

Yes

971 (66.1%)

47 (69.1%)

186 (68.4%)

47 (69.1%)

Diabetes

0.065

0.008

Yes

631 (42.9%)

27 (39.7%)

109 (40.1%)

27 (39.7%)

CVD

0.042

0.044

Yes

661 (45.0%)

32 (47.1%)

134 (49.3%)

32 (47.1%)

Hypertension

0.159

0.08

Yes

1100 (74.8%)

46 (67.6%)

194 (71.3%)

46 (67.6%)

Creatinine

0.059

0.002

Mean (SD)

1.79 (1.47)

1.72 (1.02)

1.71 (1.23)

1.72 (1.02)

Other Drug use at baseline

ACE Inhibitors use

492 (33.5%)

22 (32.4%)

0.024

91 (33.5%)

22 (32.4%)

0.023

ARB use

238 (16.2%)

9 (13.2%)

0.083

30 (11.0%)

9 (13.2%)

0.068

Antihypertensive agents use

1021 (69.5%)

47 (69.1%)

0.007

195 (71.7%)

47 (69.1%)

0.056

Diuretics use

653 (44.4%)

23 (33.8%)

0.218

94 (34.6%)

23 (33.8%)

0.016

Insulin use

298 (20.3%)

10 (14.7%)

0.147

42 (15.4%)

10 (14.7%)

0.021

Statins use

843 (57.3%)

38 (55.9%)

0.030

163 (59.9%)

38 (55.9%)

0.082